Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPAND: Aflibercept Dosing Intervals in Wet AMD
NCT05473715Phase 4Terminated
- Sponsor
- Bayer
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Bayer. Started Apr 2023; status: terminated.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05473715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473715.